Arrowhead Research Corp. (NASDAQ:ARWR) shares saw unusually-strong trading volume on Monday . Approximately 374,548 shares traded hands during mid-day trading, an increase of 16% from the previous session’s volume of 321,583 shares.The stock last traded at $5.87 and had previously closed at $5.96.

A number of equities analysts have recently issued reports on ARWR shares. Vetr upgraded shares of Arrowhead Research Corp. from a “hold” rating to a “strong-buy” rating and set a $7.88 price objective for the company in a research note on Wednesday, April 20th. Chardan Capital assumed coverage on shares of Arrowhead Research Corp. in a research report on Thursday, May 19th. They set a “buy” rating and a $12.00 target price for the company. Finally, Jefferies Group reiterated a “hold” rating and set a $4.75 target price on shares of Arrowhead Research Corp. in a research report on Wednesday, May 11th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $10.27.

The firm’s 50 day moving average is $5.68 and its 200-day moving average is $5.07. The company’s market capitalization is $351.37 million.

Arrowhead Research Corp. (NASDAQ:ARWR) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02. On average, equities analysts forecast that Arrowhead Research Corp. will post ($1.40) earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.